DNA damage response and DNA repair - dog as a model?

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Grosse, Nicole ^a   Van Loon, Barbara ^a   Rohrer Bley, Carla ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Canine and human tumors; DNA damage response; DNA repair

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53; RAD51 PROTEIN;

ARTICLE; BOCAVIRUS; BREAST CANCER; CANINE GENOME; CARCINOGENESIS; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA END JOINING REPAIR; DNA REPAIR; DOG; EXCISION REPAIR; GENE MUTATION; GENOME; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN GENOME; NONHUMAN; OSTEOSARCOMA; PROSTATE CANCER; SKIN CANCER; TUMOR GROWTH; TUMOR MODEL; TUMOR SUPPRESSOR GENE;

ANIMALS; DNA DAMAGE; DNA REPAIR; DOG DISEASES; DOGS; EVOLUTION, MOLECULAR; GENOME; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84899093140     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-203     Document Type: Article

References (59)

1. Gamulin M, Garaj-Vrhovac V, Kopjar N. Evaluation of DNA damage in radiotherapy-treated cancer patients using the alkaline comet assay. Coll Antropol 2007, 31(3):837-845.
2. Nascimento PA, da Silva MA, Oliveira EM, Suzuki MF, Okazaki K. Evaluation of radioinduced damage and repair capacity in blood lymphocytes of breast cancer patients. Braz J Med Biol Res 2001, 34(2):165-176. 10.1590/S0100-879X2001000200003, 11175491.
3. Palyvoda O, Polanska J, Wygoda A, Rzeszowska-Wolny J. DNA damage and repair in lymphocytes of normal individuals and cancer patients: studies by the comet assay and micronucleus tests. Acta Biochim Pol 2003, 50(1):181-190.
4. Smith TR, Miller MS, Lohman KK, Case LD, Hu JJ. DNA damage and breast cancer risk. Carcinogenesis 2003, 24(5):883-889. 10.1093/carcin/bgg037, 12771032.
5. Walczak A, Rusin P, Dziki L, Zielinska-Blizniewska H, Olszewski J, Majsterek I. Evaluation of DNA double strand breaks repair efficiency in head and neck cancer. DNA and cell biology 2012, 31(3):298-305. 10.1089/dna.2011.1325, 3300081, 21875370.
6. Li W, Li F, Huang Q, Shen J, Wolf F, He Y, Liu X, Hu YA, Bedford JS, Li CY. Quantitative, noninvasive imaging of radiation-induced DNA double-strand breaks in vivo. Cancer Res 2011, 71(12):4130-4137. 10.1158/0008-5472.CAN-10-2540, 3117017, 21527553.
7. Jaamaa S, Af Hallstrom TM, Sankila A, Rantanen V, Koistinen H, Stenman UH, Zhang Z, Yang Z, De Marzo AM, Taari K, Ruutu M, Andersson LC, Laiho M. DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res 2010, 70(21):8630-8641. 10.1158/0008-5472.CAN-10-0937, 20978201.
8. Slyskova J, Korenkova V, Collins AR, Prochazka P, Vodickova L, Svec J, Lipska L, Levy M, Schneiderova M, Liska V, Holubec L, Kumar R, Soucek P, Naccarati A, Vodicka P. Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. Clin Cancer Res 2012, 18(21):5878-5887. 10.1158/1078-0432.CCR-12-1380, 22966016.
9. Somaiah N, Yarnold J, Daley F, Pearson A, Gothard L, Rothkamm K, Helleday T. The relationship between homologous recombination repair and the sensitivity of human epidermis to the size of daily doses over a 5-week course of breast radiotherapy. Clin Cancer Res 2012, 18(19):5479-5488. 10.1158/1078-0432.CCR-10-3297, 22855580.
10. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, Dowsett M, Ashworth A, Turner NC. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res: an Off J of the Am Assoc for Cancer Res 2010, 16(24):6159-6168.
11. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S. The dog as a cancer model. Nat Biotechnol 2006, 24(9):1065-1066.
12. Klopfleisch R, von Euler H, Sarli G, Pinho SS, Gartner F, Gruber AD. Molecular carcinogenesis of canine mammary tumors: news from an old disease. Vet Pathol 2011, 48(1):98-116. 10.1177/0300985810390826, 21149845.
13. Modiano JF, Ritt MG, Wojcieszyn J. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. J Vet Intern Med 1999, 13(3):163-174. 10.1111/j.1939-1676.1999.tb02173.x, 10357103.
14. Veldhoen N, Stewart J, Brown R, Milner J. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene 1998, 16(2):249-255. 10.1038/sj.onc.1201489, 9464543.
15. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000, 18(8):781-792. 10.3109/07357900009012210, 11107448.
16. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008, 8(2):147-156. 10.1038/nrc2273, 18202698.
17. Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F. Canine tumors: a spontaneous animal model of human carcinogenesis. Transl Res 2012, 159(3):165-172. 10.1016/j.trsl.2011.11.005, 22340765.
18. Egenvall A, Bonnett BN, Hedhammar A, Olson P. Mortality in over 350,000 insured Swedish dogs from 1995-2000: II. Breed-specific age and survival patterns and relative risk for causes of death. Acta Vet Scand 2005, 46(3):121-136. 10.1186/1751-0147-46-121, 1624818, 16261925.
19. Rivera P, Melin M, Biagi T, Fall T, Haggstrom J, Lindblad-Toh K, von Euler H. Mammary tumor development in dogs is associated with BRCA1 and BRCA2. Cancer Res 2009, 69(22):8770-8774. 10.1158/0008-5472.CAN-09-1725, 19887619.
20. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, DeJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438(7069):803-819. 10.1038/nature04338, 16341006.
21. Ostrander EA, Wayne RK. The canine genome. Genome Res 2005, 15(12):1706-1716. 10.1101/gr.3736605, 16339369.
22. Webber C, Ponting CP. Hotspots of mutation and breakage in dog and human chromosomes. Genome Res 2005, 15(12):1787-1797. 10.1101/gr.3896805, 1356117, 16339377.
23. Luo Y, Chen AY, Qiu J. Bocavirus infection induces a DNA damage response that facilitates viral DNA replication and mediates cell death. J Virol 2011, 85(1):133-145. 10.1128/JVI.01534-10, 3014208, 21047968.
24. Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship. Chromosom Res 2008, 16(1):145-154.
25. Cruz Cardona JA, Milner R, Alleman AR, Williams C, Vernau W, Breen M, Tompkins M. BCR-ABL translocation in a dog with chronic monocytic leukemia. Vet Clin Pathol 2011, 40(1):40-47. 10.1111/j.1939-165X.2010.00277.x, 21143615.
26. Brunner S, Herndler-Brandstetter D, Arnold CR, Wiegers GJ, Villunger A, Hackl M, Grillari J, Moreno-Villanueva M, Burkle A, Grubeck-Loebenstein B. Upregulation of miR-24 is associated with a decreased DNA damage response upon etoposide treatment in highly differentiated CD8(+) T cells sensitizing them to apoptotic cell death. Aging cell 2012, 11(4):579-587. 10.1111/j.1474-9726.2012.00819.x, 3427896, 22435726.
27. Wu CW, Dong YJ, Liang QY, He XQ, Ng SS, Chan FK, Sung JJ, Yu J. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS One 2013, 8(2):e57036. 10.1371/journal.pone.0057036, 3578802, 23437304.
28. Nasir L, Argyle DJ. Mutational analysis of the tumour suppressor gene p53 in lymphosarcoma in two bull mastiffs. Vet Rec 1999, 145(1):23-24. 10.1136/vr.145.1.23, 10452395.
29. Nasir L, Argyle DJ, McFarlane ST, Reid SW. Nucleotide sequence of a highly conserved region of the canine p53 tumour suppressor gene. DNA Seq 1997, 8(1-2):83-86.
30. Nasir L, Burr PD, McFarlane ST, Gault E, Thompson H, Argyle DJ. Cloning, sequence analysis and expression of the cDNAs encoding the canine and equine homologues of the mouse double minute 2 (mdm2) proto-oncogene. Cancer Lett 2000, 152(1):9-13. 10.1016/S0304-3835(99)00427-9, 10754200.
31. Nasir L, Rutteman GR, Reid SW, Schulze C, Argyle DJ. Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas. Cancer Lett 2001, 174(1):83-89. 10.1016/S0304-3835(01)00637-1, 11675155.
32. Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF. Expression and significance of p53, rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol 2002, 39(4):458-472. 10.1354/vp.39-4-458, 12126149.
33. Lewis JS. p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 2012, 6(Suppl 1):S75-S82. 3394161, 22782226.
34. von Knebel DM, Reuschenbach M, Schmidt D, Bergeron C. Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics 2012, 9(2):149-163. 10.1586/epr.12.13, 22462787.
35. Mihic-Probst D, Mnich CD, Oberholzer PA, Seifert B, Sasse B, Moch H, Dummer R. p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer 2006, 118(9):2262-2268. 10.1002/ijc.21608, 16331607.
36. Straume O, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000, 6(5):1845-1853.
37. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Canc 2009, 9(6):400-414.
38. Castillo VA, Gallelli MF. Corticotroph adenoma in the dog: pathogenesis and new therapeutic possibilities. Res Vet Sci 2010, 88(1):26-32. 10.1016/j.rvsc.2009.07.005, 19733374.
39. Maeda J, Yurkon CR, Fujisawa H, Kaneko M, Genet SC, Roybal EJ, Rota GW, Saffer ER, Rose BJ, Hanneman WH, Thamm DH, Kato TA. Genomic instability and telomere fusion of canine osteosarcoma cells. PLoS One 2012, 7(8):e43355. 10.1371/journal.pone.0043355, 3420908, 22916246.
40. Tang J, Le S, Sun L, Yan X, Zhang M, Macleod J, Leroy B, Northrup N, Ellis A, Yeatman TJ, Liang Y, Zwick ME, Zhao S. Copy number abnormalities in sporadic canine colorectal cancers. Genome Res 2010, 20(3):341-350. 10.1101/gr.092726.109, 2840980, 20086242.
41. Legare ME, Bush J, Ashley AK, Kato T, Hanneman WH. Cellular and phenotypic characterization of canine osteosarcoma cell lines. J Cancer Educ 2011, 2:262-270.
42. Lorenzini A, Johnson FB, Oliver A, Tresini M, Smith JS, Hdeib M, Sell C, Cristofalo VJ, Stamato TD. Significant correlation of species longevity with DNA double strand break recognition but not with telomere length. Mech Ageing Dev 2009, 130(11-12):784-792. 2799038, 19896964.
43. Park SH, Kang HJ, Kim HS, Kim MJ, Heo JI, Kim JH, Kho YJ, Kim SC, Kim J, Park JB, Lee JY. Higher DNA repair activity is related with longer replicative life span in mammalian embryonic fibroblast cells. Biogerontology 2011, 12(6):565-579. 10.1007/s10522-011-9355-2, 21879286.
44. Meek K, Kienker L, Dallas C, Wang W, Dark MJ, Venta PJ, Huie ML, Hirschhorn R, Bell T. SCID in Jack Russell terriers: a new animal model of DNA-PKcs deficiency. J Immunol 2001, 167(4):2142-2150.
45. Perrault R, Wang H, Wang M, Rosidi B, Iliakis G. Backup pathways of NHEJ are suppressed by DNA-PK. J Cell Biochem 2004, 92(4):781-794. 10.1002/jcb.20104, 15211575.
46. Klopfleisch R, Gruber AD. Increased expression of BRCA2 and RAD51 in lymph node metastases of canine mammary adenocarcinomas. Vet Pathol 2009, 46(3):416-422. 10.1354/vp.08-VP-0212-K-FL, 19176491.
47. Nieto A, Perez-Alenza MD, Del Castillo N, Tabanera E, Castano M, Pena L. BRCA1 expression in canine mammary dysplasias and tumours: relationship with prognostic variables. J Comp Pathol 2003, 128(4):260-268. 10.1053/jcpa.2002.0631, 12834609.
48. Osmond CB. Salt responses of carboxylation enzymes from species differing in salt tolerance. Plant Physiol 1972, 49(2):260-263. 10.1104/pp.49.2.260, 365941, 16657937.
49. Offer H, Zurer I, Banfalvi G, Reha'k M, Falcovitz A, Milyavsky M, Goldfinger N, Rotter V. p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Res 2001, 61(1):88-96.
50. Brown MF, Stuart JA. Correlation of mitochondrial superoxide dismutase and DNA polymerase beta in mammalian dermal fibroblasts with species maximal lifespan. Mech Ageing Dev 2007, 128(11-12):696-705.
51. Waters DJ, Shen S, Glickman LT, Cooley DM, Bostwick DG, Qian J, Combs GF, Morris JS. Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model. Carcinogenesis 2005, 26(7):1256-1262.
52. Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res 1991, 270:159-168.
53. Withrow SJ, Wilkins RM. Cross talk from pets to people: translational osteosarcoma treatments. ILAR J 2010, 51(3):208-213. 10.1093/ilar.51.3.208, 21131721.
54. Munday JS, Kiupel M. Papillomavirus-associated cutaneous neoplasia in mammals. Vet Pathol 2010, 47(2):254-264. 10.1177/0300985809358604, 20106770.
55. Nikula KJ, Benjamin SA, Angleton GM, Saunders WJ, Lee AC. Ultraviolet radiation, solar dermatosis, and cutaneous neoplasia in beagle dogs. Radiat Res 1992, 129(1):11-18. 10.2307/3577898, 1728052.
56. Sokolowska J, Cywinska A, Malicka E. p53 expression in canine lymphoma. J Vet Med 2005, 52(4):172-175.
57. Sueiro FA, Alessi AC, Vassallo J. Canine lymphomas: a morphological and immunohistochemical study of 55 cases, with observations on p53 immunoexpression. J Comp Pathol 2004, 131(2-3):207-213.
58. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med 2003, 138(10):819-830. 10.7326/0003-4819-138-10-200305200-00010, 12755554.
59. Deutsch E, Dugray A, AbdulKarim B, Marangoni E, Maggiorella L, Vaganay S, M'Kacher R, Rasy SD, Eschwege F, Vainchenker W, Turhan AG, Bourhis J. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001, 97(7):2084-2090. 10.1182/blood.V97.7.2084, 11264175.